The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia

Nada Abu-Shraie, Afaf Al-Sheikh, Ibtisam Alharbi, Layla Alanizy, Mohammed Alshraim, Sahal I Khoshhal, Sarah A AlSalman, Ali Alrumaih, Ahmad Nader Fasseeh, Baher Elezbawy, Nada Abaza, Amr Semida, Marina George, Shireen Amin, Yousef Binamer · 2026

Read The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia by Nada Abu-Shraie, Afaf Al-Sheikh, Ibtisam Alharbi, Layla Alanizy, Mohammed Alshraim, Sahal I Khoshhal, Sarah A AlSalman, Ali Alrumaih, Ahmad Nader Fasseeh, Baher Elezbawy, Nada Abaza, Amr Semida, Marina George, Shireen Amin, Yousef Binamer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271258.txt.

Description

Nada Abu-Shraie is lead author of a 2026 economic analysis of upadacitinib for moderate-to-severe atopic dermatitis, a long-lasting itchy skin disease, in Saudi Arabia. The study used mathematical models to judge whether the drug gives good value to the public payer and what wider use would do to budgets.

Over a lifetime model, upadacitinib at 15 milligrams gave 0.21 extra quality-adjusted life years, years lived in good health, and cost less than the comparison drug dupilumab by an amount given in Saudi riyals. Raising its market share over five years was linked to estimated savings of 1.5 billion riyals. The authors caution that model inputs and local data limits add uncertainty.

Catalog record

CREATORNada Abu-Shraie, Afaf Al-Sheikh, Ibtisam Alharbi, Layla Alanizy, Mohammed Alshraim, Sahal I Khoshhal, Sarah A AlSalman, Ali Alrumaih, Ahmad Nader Fasseeh, Baher Elezbawy, Nada Abaza, Amr Semida, Marina George, Shireen Amin, Yousef Binamer
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43480
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13271258

Browse the full library · About the Tower of Babel